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a b s t r a c t
Objectives: Although the biological rationale for the association between folate, vitamin B12, and ho-
mocysteine with cognitive function seems plausible, conﬂicting results have been reported. This study
aimed to determine the associations between 1-carbon (1-C) metabolism biomarkers (folate, vitamin
B12, and homocysteine), and cognitive impairment at baseline and the rate of cognitive decline over
5 years in the very old.
Design: The Newcastle 85þ Study was a prospective longitudinal study of people 85 years old and fol-
lowed over 5 years in Northeast England.
Setting: Community-dwelling and institutionalized.
Participants: The analytical sample included 765 very old participants with 1-C metabolism biomarkers
and cognitive measures.
Measurements: Global cognition was measured by the Standardized Mini-Mental State Examination
(SMMSE) at baseline, and at 3 and 5 years of follow-up and, attention-speciﬁc cognition with the
Cognitive Drug Research (CDR) System at baseline, and at 1.5 and 3.0 years of follow-up. Baseline red
blood cell folate (RBC folate), plasma vitamin B12, and total homocysteine (tHcy) concentrations were
determined by immunoassay. Linear mixed models were used to estimate the associations between
quartiles of 1-C metabolism biomarkers and cognition over 3 (CDR) and 5 years (SMMSE).
Results: Comparedwith participants in the lowest quartile of RBC folate concentrations (<612 nmol/L), those
in the highest quartile of RBC folate concentrations (>1280 nmol/L) had 1 more point on the SMMSE at
baseline (b¼þ1.02, SE¼0.43,P¼ .02). Those inquartile4of tHcy(>21.4mmol/L)had1point less in theSMMSE
at baseline than those in the lowest quartile (<13.5mmol/L) (b¼1.05, SE¼ 0.46, P¼ .02). Plasmavitamin B12
was not predictive of global or attention-speciﬁc cognition at baseline and at follow-up. None of the 1-C
metabolism biomarkers except tHcy was associated with the rate of decline in attention scores over 3 years.
Conclusion: RBC folate and tHcy, but not plasma vitamin B12, were associated with better global
cognition in the very old at baseline but were not predictive of rate of decline over 5 years.
 2017 AMDA e The Society for Post-Acute and Long-Term Care Medicine. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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There are now 46.8 million people with dementia worldwide, and
that number is predicted to reach 74.7 million by 2030.1 The Cognitive
Function and Ageing Study (CFAS) II estimated that there were
670,000 older adults with dementia in 2011 in England alone.2 Despite
some evidence of reduction in the prevalence and incidence of de-
mentia,2,3 it is predicted that cases of dementia will increase primarily
for the following reasons: (1) dementia incidence doubles every
6.3 years after 60 years old1; and (2) the population is aging world-
wide predominantly because of the rise in the numbers of the very old
(85 years and older), the fastest growing age segment in the United
Kingdom and most Western societies.4 Dementia is one of the most
important predictors of disability and poses a major societal chal-
lenge.5 Because cognitive decline and dementia affect quality of life
detrimentally and are currently not treatable, research priorities have
focused on preventing or delaying the onset of dementia through
modiﬁable risk factors, such as nutrition.6
Folate and vitamin B12 are B vitamins that are central to 1-carbon
(1-C) metabolism. Inadequate or aberrant 1-C metabolism may be
associated with cognitive function through mechanisms such as
hyperhomocysteinemia7; reduced synthesis of neurotransmitters,
phosphatidylcholine, and pyrimidines8; altered DNA methylation
patterns9; and reduced fatty acid synthesis and incorporation of odd
chain fatty acids into the myelin sheath.10
Although the biological rationale for associations between folate,
vitamin B12, and homocysteine with cognitive function seem plau-
sible, conﬂicting results have been reported. Folate, vitamin B12, and
homocysteine have been associated with cognitive decline in some
longitudinal studies,11e13 but not all,14e17 in some randomized
controlled trials (RCTs),18e20 for one vitamin but not the other, or only
for certain cognitive domains. Insufﬁcient follow-up time, small
sample size, participants’ age at recruitment, and different cognitive
tests used are frequently reported reasons for the conﬂicting results.
Furthermore, studies targeting the very old are lacking. We hypoth-
esized that higher red blood cell (RBC) folate and plasma vitamin B12
concentrations would be associated with better cognitive perfor-
mance and slower rate of cognitive decline, primarily through
homocysteine-lowering effects. This study aimed to determine the
associations between RBC folate, plasma vitamin B12, and total ho-
mocysteine (tHcy) concentrations at baseline, and cognitive impair-
ment and the rate of cognitive decline in global and attention-speciﬁc
cognition over 5 years in a large population of the very old who
participated in the Newcastle 85þ Study.
Methods
Participants
Brieﬂy, the Newcastle 85þ Study is a longitudinal study of health
trajectories and outcomes in the very old that approached virtually all
people turning 85 in 2006 (born in 1921) in North East England. The
recruited cohort was broadly sociodemographically representative of
the general UK population and, included institutionalized and cogni-
tively impaired very old adults,21 2 commonly excluded groups. Data
were collected on multidimensional health aspects and general
practice medical records were reviewed at baseline (2006/2007),
18 months (1.5 years), 36 months (3 years), and 60 months later
(5 years)22 (Figure A1). Further information is reported elsewhere21e24
(for study questionnaires visit http://research.ncl.ac.uk/85plus).
Biomarkers of 1-C Metabolism
Forty milliliters of blood were drawn from the antecubital vein
between 7:00 and 10:30 AM after an overnight fast, and 95% of the
samples reached the laboratory within 1 hour. Both RBC folate and
plasma vitamin B12 were quantiﬁed by chemiluminescence
(Microparticle Immunoassay on Abbott ARCHITECT analyzer [Abbot
Park, IL]) and tHcy by an Abbot IMx immunoassay at baseline.25
Cognitive Assessment
The Standardized Mini-Mental State Examination (SMMSE) was
used to assess global cognitive status at baseline and 3- (36 months)
and 5-year (60 months) follow-up (Figure A1). The SMMSE is a short,
standardized screening test for cognitive impairment in older adults
that ranks global cognitive function from 0 to 30. Individuals with
SMMSE scores26 were considered as healthy and25 as cognitively
impaired.26 Three automated tests of attention from the Cognitive
Drug Research (CDR) Systemwere used to assess cognition at baseline
and again after 1.5 (18 months) and 3.0 years (36 months) (Figure A1).
The tests were simple reaction time (SRT), which assesses focused
attention and concentration; choice reaction time (CRT), which
assessed similar abilities in addition to information processing and
decision making; and the digit vigilance task (DVT) that assesses the
ability to sustain attention.27 Using the measures of speed and accu-
racy from the tasks, 3 validated composite measures were derived:
power of attention (PoA), the sum of 3 speed scores that reﬂects the
ability to focus attention and the intensity of concentration; reaction
time variability (RTV), which is a sum of the coefﬁcients of variance of
the reaction time scores and reﬂects variations in attention during the
tasks; and continuity of attention (CoA), which combines the accuracy
scores from CRT and DVT and reﬂects the ability to sustain atten-
tion.28,29 All 3 of these composite scores have been validated previ-
ously.30,31 Higher scores in the SMMSE and the CoA, and lower scores
for the PoA and RTV measures reﬂect superior performance.
Other Confounders
Whole-blood DNA was extracted fusing a QiaGEN (Hilden, Ger-
many) Amp Maxi DNA Puriﬁcation Kit and the gene encoding apoli-
poprotein E (APOE) genotyped for common polymorphisms at
rs429358 and rs7412 (to provide information on zygosity at ε2, ε3, and
ε4 alleles) by Illumina Omni (San Diego, CA) genotyping arrays.25
Multidimensional health questionnaires recorded sex, current hous-
ing, years of full-time education, depression (Geriatric Depression
Scale), physical activity, supplement use,32 alcohol intake (conﬁrmed
by 2  24-hour multiple pass recalls33), and smoking status. Medical
records held by the general practitioner were reviewed for diagnosed
dementia/Alzheimer disease, diabetes type 1 and 2, hypertension, and
history of cardiovascular disease (including angina, myocardial
infarction, coronary angioplasty, coronary artery bypass graft, atrial
ﬁbrillation, atrial ﬂutter, heart failure, pacemaker use, stroke, transient
ischemic attack, and carotid endarterectomy).Weight and height were
measured and used to calculate body mass index (BMI). Renal
impairment was determined by the chronic kidney disease epidemi-
ology collaboration (CKD-EPI) guidelines using sex, ethnicity, serum
creatinine, and age.34
Statistical Analysis
Statistical analyses were conducted using SPSS v22.0 (IBM SPSS
Statistics, IBM Corporation, Chicago, IL). Normality was assessed with
the Shapiro-Wilk test and conﬁrmed with histograms and Q-Q plots.
Linearity assumptions were tested with residuals versus predicted
values plots. Multicollinearity of confounders was assessed with
variance inﬂation factor, tolerance, and eigenvalues. Normally
distributed continuous values are presented as means and SDs, and
non-Gaussianedistributed variables as medians and interquartile
ranges (IQRs). Categorical data are presented as percentages (with
corresponding sample size). Differences between quartiles of RBC
folate, plasma vitamin B12, and tHcy were assessed with c2 test for
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categorical variables, Mann-Whitney U test for continuous nonpara-
metric data, and 1-way analysis of variance for parametric variables.
To account for within-person variability and missing values, the
longitudinal effects of RBC folate, plasma vitamin B12, and tHcy on
cognitive function were assessed by linear mixed models. Random ef-
fects terms included both intercept and slopes of SMMSE and attention
scores with the time in the study coded as 0 (baseline), 1 (1.5 or
3.0 years), or 2 (3 or 5 years), respectively. Parameters (b coefﬁcients)
were estimated by the maximum likelihood method and the model
followed an autoregressive heterogeneous covariance structure. RTV
was logarithmically (ln) transformed to correct a positive skew and aid
convergence. Other attention scores (PoA and CoA) by 1-C biomarkers
were not transformed because the distribution of the residuals of each
respective linear mixed model was roughly normal and this did not
interfere with convergence. An interaction between the biomarker and
time was added to assess the rate of cognitive decline.
Binary logistic regression models were ﬁtted to predict cognitive
impairment (SMMSE 25) at baseline and incident cognitive impair-
ment after 3 and 5 years. All models were adjusted for sex, APOE e4
genotype (rs429358 and rs7412), hypertension, diabetes type 1 and 2,
history of cardiovascular diseases, depression, alcohol intake, smoking
status, physical activity, years of full-time education, BMI, homocys-
teine in the folate and vitamin B12 models, and renal impairment in
the homocysteine models.
In sensitivity analyses, all models were re-run after excluding
participants diagnosed with Alzheimer disease/dementia or living in
institutions at baseline, use of folic acid/vitamin B12-containing sup-
plements, with RBC folate concentrations >4000 nmol/L, plasma
vitamin B12 concentrations >1000 pmol/L, or tHcy concentrations
>40 mmol/L. P < .05 was considered statistically signiﬁcant, unless
otherwise stated.
Results
Population Characteristics by 1-C Metabolism Biomarkers
The 1-C metabolism biomarkers and SMMSE data were available
for 752 to 765 participants at baseline, 414 to 450 at 3 years, and 311 to
318 at 5 years (Figure A1). Attention-speciﬁc scores (CDR) were
available for 705 to 718 participants at baseline, 528 to 538 at 1.5 years,
and 391 to 400 at 3.0 years, depending on the 1-C metabolism assay
used (Figure A1). The median concentration for tHcy, RBC folate, and
plasma vitamin B12 was 16.7 mmol/L (IQR 13.5e21.4), 863 nmol/L (IQR
451e1287), and 232 pmol/L (IQR 170e324), respectively in the New-
castle 85þ Study.25 A concentration >15 mmol/L of tHcy is commonly
used to deﬁne hyperhomocysteinemia, and concentrations
<340 nmol/L and <148 pmol/L to deﬁne inadequacy of RBC folate and
plasma vitamin B12, respectively. Sixty-three percent of the cohort
(n ¼ 482) had tHcy concentrations >15 mmol/L, 4% (n ¼ 26) had RBC
folate concentrations <340 nmol/L, and 17% (n ¼ 125) had plasma
vitamin B12 concentrations <148 pmol/L.25 Tables 1e3 show the
population characteristics at baseline and cognitive scores at follow-
up by quartile of RBC folate (quartile 1 [Q1]: <612, Q2: 612e870,
Q3: 870e1280, Q4: >1280 nmol/L), plasma vitamin B12 (Q1: >170,
Q2: 170e232, Q3: 232e325, Q4: >325 pmol/L), and tHcy (Q1: >13.5,
Q2: 13.5e16.7, Q3: 16.7e21.4, Q4: >21.4 mmol/L), respectively. There
Table 1
Population Characteristics and Cognitive Test Scores at Baseline and Follow-up in the Newcastle 85þ Study by Quartile of RBC Folate Concentration
Q1, <612 nmol/L Q2, 612e870 nmol/L Q3, 870e1280 nmol/L Q4, >1280 nmol/L P*
Men, % (n) 41 (77) 38 (72) 40 (75) 38 (72) .86
BMI, mean (SD), kg/m2 24.2 (4.3) 24.7 (4.5) 24.3 (4.1) 24.4 (4.3) .78y
APOE ε4 carriers, % (n) 32 (49) 17 (25) 30 (47) 28 (42) .02
Plasma vitamin B12, pmol/L 201 (135e280) 216 (159e275) 259 (193e371) 278 (205e391) <.001
tHcy, mmol/L 19.9 (16.3e24.6) 18.3 (14.9e22.9) 15.6 (13.0e19.6) 13.8 (11.1e17.4) <.001
Alcohol drinkers, % (n) 70 (92) 73 (94) 80 (96) 66 (89) .10
Smokers, % (n) 9 (16) 4 (8) 4 (8) 5 (10) .35
Physical activity, high, % (n) 38 (71) 33 (62) 34 (63) 37 (68) .75
Education 12 y, % (n) 11 (20) 11 (20) 14 (25) 14 (26) .18
History of cardiovascular disease, % (n) 45 (84) 57 (108) 66 (123) 63 (119) <.001
Diabetes type 1 or 2, % (n) 9 (16) 16 (31) 13 (25) 17 (32) .08
Hypertension, % (n) 54 (100) 59 (112) 54 (101) 65 (122) .12
Renal impairment, % (n) 20 (38) 26 (49) 22 (41) 28 (52) .36
Depression, severe, % (n) 4 (7) 10 (19) 11 (19) 9 (16) .25
Global cognition (SMMSE)
Baseline 27 (24e29) 28 (25e29) 28 (25e29) 28 (25e29) .17
Impaired, 25, % (n) 31 (58) 25 (48) 26 (49) 25 (48) .52
3 y 27 (23e29) 28 (24e29) 26 (23e29) 27 (25e29) .19
Impaired, 25, % (n) 37 (41) 35 (35) 40 (48) 25 (27) .10
5 y 28 (23e29) 27 (23e29) 27 (23e28) 28 (25e29) .17
Impaired, 25, % (n) 32 (26) 37 (27) 43 (33) 26 (21) .16
Focused attention (PoA, ms)
Baseline 1499 (1341e1691) 1494 (1371e1752) 1484 (1360e1719) 1473 (1341e1667) .54
1.5 y 1546 (1398e1745) 1538 (1377e1740) 1533 (1399e1731) 1515 (1366e1718) .84
3.0 y 1594 (1409e1777) 1567 (1378e1775) 1550 (1420e1782) 1490 (1367e1688) .16
Sustained attention (CoA, ms)
Baseline 87.8 (80.7e91.4) 87.5 (80.8e91.0) 85.7 (77.0e91.0) 87.7 (82.3e91.3) .20
1.5 y 86.6 (79.4e90.4) 88.0 (81.9e91.6) 87.0 (78.4e90.5) 86.5 (80.8e90.9) .24
3.0 y 86.7 (81.1e91.0) 86.8 (79.4e90.7) 86.4 (78.6e90.7) 87.0 (82.2e91.5) .73
RTV
Baseline 59.1 (50.6e71.4) 61.2 (54.6e71.7) 61.5 (53.2e73.1) 57.6 (50.3e68.6) .06
1.5 y 60.0 (53.8e71.0) 60.0 (52.1e68.2) 60.2 (52.2e72.0) 57.6 (52.1e67.0) .68
3.0 y 59.9 (50.8e70.0) 59.8 (49.4e69.6) 61.4 (51.8e72.3) 59.3 (50.3e66.7) .60
Q, quartile.
Lower scores in the PoA and RTV, and higher scores in CoA reﬂect better performance. Continuous variables are presented as medians and IQR unless otherwise stated. History
of cardiovascular disease includes cardiac, cerebrovascular, and peripheral vascular diseases.
*No quartile difference by c2 for categorical or by Kruskal-Wallis test for nonparametric continuous variables.
yNo BMI difference by 1-way analysis of variance.
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were fewer APOE ε4 carriers in quartile 2 (17%) than in other quartiles
(28%e32%) of RBC folate (P¼ .002), and fewer individuals in quartile 1
with history of cardiovascular diseases (45%) than in other quartiles
(57%e63%) (P < .001). As RBC folate increased, so did plasma vitamin
B12 and vice-versa. There was an inverse association between tHcy
and the other 1-C metabolism biomarkers. There were more men in
tHcy quartile 3 (50%) than in other quartiles (P < .001). Furthermore,
participants in quartile 4 of tHcy concentrations (>21.3 mmol/L) were
less physically active and more likely to be renally impaired compared
with those in other quartiles (Table 3).
Longitudinal Associations With Cognitive Performance
Participants lost to follow-up (died or unable to complete any
cognitive test; Figure A1) after 5 years (n ¼ 501) had slightly higher
median tHcy (P ¼ .01) and plasma vitamin B12 concentrations
(P ¼ .05); were more likely to be APOE ε4 carriers (P ¼ .01); were less
likely to drink alcohol (P< .001); less physically active (P< .001); more
likely to have a history of CVD (P ¼ .003), diabetes type 1 and 2
(P ¼ .01), and Alzheimer disease/dementia (P < .001); and more likely
to live in institutions (P < .001) at baseline compared with those who
had SMMSE data 5 years later. Furthermore, more participants lost to
follow-up during every phase were more cognitively impaired than
those who continued on the study.
Table 4 shows the associations between RBC folate, plasma vitamin
B12, and tHcy quartiles and attention-speciﬁc and global cognitive
decline over 3 and 5 years, respectively, using linear mixed models.
Participants in the highest quartile of RBC folate concentrations
had 1 more point on the SMMSE at baseline than those in quartile 1
(b ¼ þ1.02, SE ¼ 0.43, P ¼ .02) after adjustment for sex, alcohol intake,
smoking status, APOE genotype, education, BMI, depression, diabetes
type 1 and 2, hypertension, history of cardiovascular disease, physical
activity, and tHcy (Table 4). Plasma vitamin B12 concentration
measured at baseline was not predictive of global cognition (SMMSE)
in the nonadjusted (data not shown) or fully adjusted models.
Conversely, participants in the highest quartile of tHcy had 1 point less
on the SMMSE score than those in the lowest quartile at baseline
(b ¼ 1.05, SE ¼ 0.46, P ¼ .02). Folate, vitamin B12, and tHcy were not
predictive of any attention-speciﬁcmeasures (PoA, CoA, and RTV) over
3 years (Table 4).
Rate of Cognitive Decline by 1-C Metabolism Biomarkers
All domains of cognitive performance declined signiﬁcantly (lower
scores of SMMSE and CoA and higher scores in PoA and RTV) with time.
SMMSE and CoA decreased on average by 1.68 (SE¼ 0.18, P < .001) and
by 1.27 ms (SE ¼ 0.3, P < .001) respectively, PoA and RTV (ln) increased
by 105 ms (SE ¼ 15, P < .001) and by 0.021 (SE ¼ 0.008, P ¼ .01)
respectively, for every phase. There were no signiﬁcant changes in the
rate of global cognitive decline (SMMSE) by quartiles of RBC folate,
plasma vitamin B12, and tHcy (Table 4). There were also no signiﬁcant
differences in the rate of decline in attention-speciﬁc scores (CDR)
except for a slower decline in focused attention (PoA) (eg, Q4 vs Q1:
b ¼ 100, SE ¼ 44, P ¼ .02) and a trend for slower decline of sustained
Table 2
Population Characteristics and Cognitive Test Scores at Baseline and Follow-up in the Newcastle 85þ Study by Quartile of Plasma Vitamin B12 Concentration
Q1, <170 pmol/L Q2, 170e232 pmol/L Q3, 232e325 pmol/L Q4, >325 pmol/L P*
Men, % (n) 42 (79) 41 (77) 39 (74) 35 (66) .56
BMI, mean (SD), kg/m2 25.1 (4.5) 23.8 (4.1) 25.0 (4.3) 23.7 (4.3) .001y
APOE ε4 carriers, % (n) 26 (40) 24 (38) 23 (35) 32 (50) .30
RBC folate, nmol/L 683 (479e992) 838 (605e1159) 913 (690e1393) 1058 (745e1608) <.001
tHcy, mmol/L 19.7 (15.9e25.1) 17.3 (14.5e21.8) 15.9 (13.3e19.8) 13.9 (11.1e18.2) <.001
Alcohol drinkers, % (n) 73 (103) 72 (91) 80 (91) 65 (86) .07
Smokers, % (n) 6 (11) 5 (10) 6 (12) 5 (9) .77
Physical activity, high, % (n) 38 (72) 37 (68) 34 (63) 33 (62) .55
Education 12 y, % (n) 10 (19) 13 (23) 14 (27) 12 (22) .15
History of cardiovascular disease, % (n) 51 (96) 60 (113) 62 (117) 57 (108) .10
Diabetes type 1 or 2, % (n) 12 (23) 18 (33) 12 (22) 13 (25) .32
Hypertension, % (n) 58 (111) 54 (100) 61 (114) 59 (110) .55
Renal impairment, % (n) 23 (44) 27 (51) 23 (44) 22 (41) .65
Depression, severe, % (n) 8 (14) 8 (14) 10 (18) 9 (15) .90
Dementia/Alzheimer, % (n) 6 (12) 8 (14) 8 (15) 6 (11) .83
Global cognition (SMMSE)
Baseline 28 (25e29) 27 (25e29) 28 (25e29) 28 (25e29) .73
Impaired 25, % (n) 28 (53) 26 (49) 27 (50) 27 (51) .99
3 y 27 (23e29) 27 (25e29) 27 (24e29) 27 (24e29) .94
Impaired 25, % (n) 40 (48) 32 (35) 31 (33) 35 (35) .47
5 y 27 (22e29) 27 (24e29) 27 (23e28) 28 (24e29) .95
Impaired 25, % (n) 38 (33) 35 (28) 32 (24) 33 (23) .83
Focused attention (PoA, ms)
Baseline 1502 (1351e1723) 1497 (1370e1710) 1482 (1356e1676) 1467 (1342e1705) .75
1.5 y 1537 (1370e1848) 1519 (1390e1799) 1548 (1402e1694) 1506 (1373e1725) .95
3.0 y 1503 (1361e1744) 1560 (1389e1778) 1555 (1425e1732) 1547 (1405e1757) .69
Sustained attention (CoA, ms)
Baseline 87.8 (80.7e91.6) 86.8 (81.5e90.9) 87.5 (18.7e91.7) 86.6 (78.5e90.8) .54
1.5 y 86.8 (81.2e90.9) 87.3 (82.0e90.8) 87.9 (79.6e91.0) 85.8 (78.9e90.7) .63
3.0 y 86.9 (81.7e91.3) 87.5 (81.0e90.4) 88.3 (81.1e91.8) 85.3 (79.6e90.0) .09
RTV
Baseline 60.9 (52.0e70.4) 60.2 (51.0e70.3) 59.6 (52.2e69.6) 58.9 (51.2e72.2) 1.00
1.5 y 60.0 (51.2e67.7) 60.1 (53.7e70.8) 60.4 (52.1e68.3) 57.3 (51.1e68.8) .45
3.0 y 59.9 (49.5e67.4) 59.8 (51.5e71.6) 59.2 (51.3e67.8) 60.9 (50.6e71.5) .74
Q, quartile.
Lower scores in PoA and RTV, and higher scores in CoA reﬂect better performance. Continuous variables are presented as medians and IQR unless otherwise stated. History of
cardiovascular disease includes cardiac, cerebrovascular. and peripheral vascular diseases.
*No quartile difference by c2 for categorical or by Kruskal-Wallis test for nonparametric continuous variables.
yNo BMI difference by 1-way analysis of variance.
N. Mendonça et al. / JAMDA xxx (2017) 1.e1e1.e91.e4
attention (CoA) (eg, Q4 vs Q1: b¼þ1.58, SE¼ 0.87, P¼ .07) in the higher
quartiles of tHcy concentration (Table 4 and Figures A2eA4).
Prevalent and Incident Cognitive Impairment
Binary logistic regressionmodels, adjusted for the same covariates,
showed that participants in Q4 of tHcy had an increased risk (odds
ratio [OR] 2.15, conﬁdence interval [CI] 1.12e4.11, P ¼ .02) of prevalent
cognitive impairment (deﬁned as SMMSE 25 points in SMMSE) than
those in Q4, but not for incident impairment after 3 years (data not
shown) or after 5 years (Table A1).
Sensitivity Analysis
Sensitivity analyses excluding those with diagnosed Alzheimer
disease/dementia (n ¼ 52e56), living in institutions at baseline
(n ¼ 61e62), use of folic acid or vitamin B12 containing supplements
(n ¼ 35e37), with RBC folate concentrations >4000 nmol/L (n ¼ 6),
plasma vitamin B12 concentrations >1000 pmol/L (n ¼ 16), or tHcy
concentrations >40 mmol/L (n ¼ 16) did not generally change the re-
sults. However, higher homocysteine quartiles were signiﬁcantly
associated with higher scores in PoA (poorer performance) over
5 years when participants diagnosed with dementia or Alzheimer
disease at baseline were excluded. The interaction between quartiles
of tHcy concentration and time for focused attention (PoA) was no
longer present when these same participants were excluded from the
analysis.
Discussion
Main Findings
This study showed that in the very old, higher quartiles of RBC
folate and lower quartiles of tHcy concentration measured at baseline
were associated with better global cognition as measured by the
SMMSE. In contrast, plasma vitamin B12 was not associated with
cognition (global and attention) at any time points. RBC folate, plasma
vitamin B12, and tHcy concentrationwere not predictive of the rate of
decline in SMMSE and attention, except for higher tHcy concentration,
which was associated with slower decline in focused attention (PoA).
Other Studies
Results of folate and global cognition and/or speciﬁc cognitive
domains in prospective cohort studies are frequently in disagreement.
This study conﬁrmed ﬁndings from studies that showed that folate, as
measured by serum folate or RBC folate, was associated with global
cognition or speciﬁc cognitive domains,11e14,35e37 whereas others did
not ﬁnd these relationships.16,17,38 However, apart from Leiden 85-
Plus, these studies focused on younger populations. Voluntary folic
acid fortiﬁcation of cereal grains products introduced in 1996 in the
United States and changed into mandatory fortiﬁcation in 1998 might
partly explain the lack of associations between folate and cognitive
performance in some studies, as it is difﬁcult to ﬁnd overt folate
deﬁciency.16 The median (IQR) RBC folate concentration in our cohort
Table 3
Population Characteristics and Cognitive Test Scores at Baseline and at Follow-up in the Newcastle 85þ Study by Quartile of tHcy Concentration
Q1, <13.5 mmol/L Q2, 13.5e16.7 mmol/L Q3, 16.7e21.4 mmol/L Q4, >21.4 mmol/L P*
Men, % (n) 32 (61) 32 (62) 50 (96) 43 (83) <.001
BMI, mean (SD), kg/m2 24.3 (4.4) 24.3 (4.3) 24.9 (4.5) 24.5 (4.3) .44y
APOE ε4 carriers, % (n) 23 (35) 28 (46) 29 (44) 26 (40) .70
RBC folate, nmol/L 1272 (896e1748) 940 (675e1279) 779 (573e1084) 680 (477e898) <.001
Plasma vitamin B12, pmol/L 297 (225e430) 230 (185e303) 225 (161e293) 186 (134e262) <.001
Alcohol drinkers, % (n) 69 (86) 73 (101) 80 (102) 68 (90) .14
Smokers, % (n) 5 (9) 3 (5) 7 (14) 8 (15) .01
Physical activity, high, % (n) 38 (72) 34 (65) 38 (72) 31 (58) .02
Education 12 y, % (n) 15 (28) 13 (25) 12 (22) 9 (17) .57
History of cardiovascular disease, % (n) 56 (106) 58 (112) 59 (113) 59 (113) .88
Diabetes type 1 or 2, % (n) 14 (27) 13 (25) 13 (25) 16 (31) .80
Hypertension, % (n) 56 (107) 52 (99) 59 (113) 63 (121) .14
Renal impairment, % (n) 8 (15) 15 (29) 22 (41) 51 (98) <.001
Depression, severe, % (n) 9 (16) 11 (19) 5 (9) 10 (18) .52
Dementia/Alzheimer, % (n) 9 (17) 8 (15) 6 (12) 7 (13) .77
Global cognition (SMMSE)
Baseline 28 (26e29) 28 (26e29) 28 (25e29) 27 (24e29) .01
Impaired, 25, % (n) 24 (46) 23 (45) 29 (55) 32 (61) .19
3 y 27 (24e29) 27 (24e29) 27 (25e29) 27 (22e29) .46
Impaired, 25, % (n) 31 (35) 30 (34) 35.0 (43) 43 (42) .17
5 y 28 (25e28) 27 (23e29) 28 (25e29) 27 (23e29) .80
Impaired, 25, % (n) 32 (28) 38 (31) 28 (24) 41 (26) .32
Focused attention (PoA, ms)
Baseline 1450 (1326e1662) 1486 (1354e1723) 1476 (1351e1659) 1517 (1409e1753) .03
1.5 y 1532 (1371e1731) 1519 (1371e1711) 1513 (1379e1724) 1601 (1444e1782) .13
3.0 y 1492 (1369e1689) 1546 (1383e1749) 1564 (1442e1786) 1559 (1406e1800) .25
Sustained attention (CoA, ms)
Baseline 87.8 (80.7e91.7) 87.6 (81.4e91.3) 87.3 (79.2e90.8) 86.3 (78.3e91.3) .44
1.5 y 86.0 (81.7e90.8) 88.2 (82.7e91.5) 88.0 (81.5e90.8) 85.1 (76.8e90.2) .02
3.0 y 86.8 (80.2e91.8) 87.5 (81.0e91.7) 87.0 (81.3e90.7) 86.3 (76.5e90.0) .35
RTV
Baseline 57.1 (50.8e67.3) 61.8 (52.0e72.1) 60.3 (51.5e72.8) 61.2 (53.0e71.8) .08
1.5 y 60.5 (53.1e71.1) 57.0 (50.8e67.0) 59.4 (52.9e67.8) 62.9 (54.0e71.4) .04
3.0 y 55.8 (49.6e67.8) 60.8 (52.0e68.6) 60.7 (51.2e72.5) 61.8 (51.6e69.7) .34
Q, quartile.
Lower scores in PoA and RTV, and higher scores in CoA reﬂect better performance. Continuous variables are presented as medians and IQR unless otherwise stated. History of
cardiovascular disease includes cardiac, cerebrovascular, and peripheral vascular diseases.
*No quartile difference by c2 for categorical or by Kruskal-Wallis test for nonparametric continuous variables.
yNo BMI difference by 1-way analysis of variance.
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was 863 (IQR 451e1287) nmol/L and only 4% (n ¼ 26) had concen-
trations <340 nmol/L. With reference to cutoffs derived from younger
populations, this RBC folate concentration might be considered
replete, which also could explain the lack of associations with cogni-
tive decline. The choice of biomarkers to assess folate status also de-
serves attention, as some studies that did not ﬁnd an association16,38
used serum folate and not RBC folate, which more closely reﬂects
long-term status.
In contrast with our ﬁndings, some studies have reported that
holotranscobalamin or plasma vitamin B12 concentration was pre-
dictive of cognitive decline,13,38e41 whereas others failed to ﬁnd an
association.12,14,16,17,35,36,39 As with our study, some studies,11e13,35,38
but not all,14,17,36,40 have reported that tHcy concentration was
associated with global cognition or speciﬁc cognitive domains
measured over time. The Leiden 85-Plus study had a very similar
design to the Newcastle 85þ study and included 599 adults aged
85 years at baseline. Participants were followed for 4 years and
global cognitive function was assessed by the Mini-Mental State
Examination and attention was measured by the Stroop test. Mooi-
jaart et al14 reported ﬁndings similar to our study. Low serum folate
and high tHcy, but not serum vitamin B12, were associated with
cognitive impairment cross-sectionally, but these biomarkers did not
predict cognitive decline or rate of cognitive decline over 4 years in
the Leiden 85-Plus. In the same study, tHcy concentration was
associated with attention at baseline but not folate or vitamin B12
and not longitudinally.14
Table 4
Association Between Folate, Vitamin B12, and Homocysteine and Attention-Speciﬁc and Global Cognitive Decline in the Newcastle 85þ Study
Biomarker Change Over Time, b (SE); P Intercept, b (SE); P Biomarker  Time, b (SE); P
Global cognitive function (SMMSE)
RBC folate, nmol/L
Q2 (612e870) 1.69 (0.18); <.001 þ0.57 (0.42); .17 0.38 (0.51); .46
Q3 (870e1280) þ0.61 (0.42); .15 0.88 (0.49); .08
Q4 (>1280) þ1.02 (0.43); .02 þ0.13 (0.51); .80
Plasma vitamin B12, pmol/L
Q2 (170e232) 1.68 (0.18); <.001 þ0.62 (0.42); .14 þ0.50 (0.49); .30
Q3 (232e325) 0.15 (0.43); .73 0.55 (0.50); .27
Q4 (>325) þ0.54 (0.43); .21 þ0.15 (0.51); .77
tHcy, mmol/L
Q2 (13.5e16.7) 1.68 (0.18); <.001 0.53 (0.41); .20 þ0.26 (0.49); .60
Q3 (16.7e21.4) 0.74 (0.43); .08 þ0.96 (0.50); .06
Q4 (>21.4) 1.05 (0.46); .02 þ0.35 (0.53); .50
Focused attention (PoA, ms)
RBC folate, nmol/L
Q2 (612e870) þ104 (15); <.001 þ19 (62); .76 10 (43); .82
Q3 (870e1280) þ20 (63); .75 þ98 (42); .02
Q4 (>1280) 45 (63); .48 þ27 (43); .52
Plasma vitamin B12, pmol/L
Q2 (170e232) þ105 (15); <.001 95 (62); .13 þ40 (42); .34
Q3 (232e325) 41 (62); .52 þ26 (43); .55
Q4 (>325) 114 (64); .07 þ35 (43); .42
tHcy, mmol/L
Q2 (13.5e16.7) þ105 (15); <.001 þ108 (61); .08 110 (42); .01
Q3 (16.7e21.4) þ53 (63); .40 93 (42); .03
Q4 (>21.4) þ81 (68); .23 100 (44); .02
Sustained attention (CoA, ms)
RBC folate, nmol/L
Q2 (612e870) 1.26 (0.30); <.001 0.91 (1.20); .45 0.34 (0.84); .69
Q3 (870e1280) 1.27 (1.22); .30 0.45 (0.83); .58
Q4 (>1280) þ1.00 (1.23); .41 1.07 (0.84); .21
Plasma vitamin B12, pmol/L
Q2 (170e232) 1.27 (0.30); <.001 þ0.76 (1.21); .53 0.45 (0.81); .58
Q3 (232e325) 1.00 (1.22); .41 0.62 (0.83); .45
Q4 (>325) 0.32 (1.24); .80 0.75 (0.84); .37
tHcy, mmol/L
Q2 (13.5e16.7) 1.27 (0.30); <.001 þ0.38 (1.18); .75 þ1.65 (0.82); .04
Q3 (16.7e21.4) þ1.58 (1.22); .20 þ2.19 (0.83); .01
Q4 (>21.4) þ0.04 (1.32); .98 þ1.58 (0.87); .07
RTV
RBC folate, nmol/L
Q2 (612e870) þ0.021 (0.008); .01 þ0.017 (0.026); .52 0.037 (0.022); .09
Q3 (870e1280) þ0.043 (0.027); .10 þ0.001 (0.021); .97
Q4 (>1280) 0.019 (0.027); .49 þ0.028 (0.022); .20
Plasma vitamin B12, pmol/L
Q2 (170e232) þ0.021 (0.008); .01 þ0.015 (0.026); .58 þ0.001 (0.021); .95
Q3 (232e325) þ0.034 (0.027); .20 0.017 (0.021); .44
Q4 (>325) þ0.010 (0.027); .72 0.015 (0.022); .49
tHcy, mmol/L
Q2 (13.5e16.7) þ0.021 (0.008); .01 þ0.016 (0.026); .53 þ0.035 (0.028); .22
Q3 (16.7e21.4) þ0.018 (0.027); .49 þ0.030 (0.030); .31
Q4 (>21.4) þ0.034 (0.029); .24 þ0.042 (0.031); .18
Q, quartile.
For all models, Q1 (<612 nmol/L RBC folate, <170 pmol/L plasma vitamin B12, and <13.5 tHcy, respectively) was used as the reference (0.00). Models are adjusted for alcohol
intake, smoking status, APOE genotype (rs429358 and rs7412), sex, education, BMI, depression, hypertension, diabetes type 1 and 2, history of cardiovascular diseases, and
physical activity. RBC folate and plasma vitamin B12 models were additionally adjusted for tHcy and the homocysteine model for renal impairment. Higher scores in the
SMMSE and CoA, and lower scores in PoA and RTV tests represent better performance.
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The lack of speciﬁcity of the assay used for plasma vitamin B12may
explain the lack of associations between cognitive decline and vitamin
B12 in the Newcastle 85þ Study and the Leiden 85-Plus. The assay
assesses not only the vitamin’s active form, holotranscobalamin,
which makes up 20% to 30% of plasma vitamin B12, but also the other
70% to 80% bound to haptocorrin and considered inert.42 The use of
more recent and more robust markers of vitamin status, such as
holotranscobalamin and methylmalonic acid (MMA), might have
yielded different results. In fact, a review of longitudinal cohort
studies of vitamin B12 status and cognitive decline found that, in all
studies in which holotranscobalamin and MMA had been used, asso-
ciations between vitamin B12 status and cognitive decline, dementia,
or Alzheimer disease were present.43 Those with obvious dementia
usually show no improvement when treated with vitamin B12.44 In
the Newcastle 85þ Study, 9% of the participants had been diagnosed
with dementia/Alzheimer disease at baseline, which might have
skewed the results and partly explained the lack of association.
However, in sensitivity analyses, when we excluded participants with
dementia from the models, the lack of association between plasma
vitamin B12 and cognitive performance at baseline and at follow-up
remained. Very high plasma vitamin B12 concentrations have been
found in patients with inﬂammatory, liver, and kidney diseases, which
could underestimate the association with cognitive performance.45
Therefore, models were re-run excluding those with plasma vitamin
B12 concentrations greater than 1000 pmol/L, but the results were
similar. Perhaps the most convincing data so far from RCTs on the
association between B vitamins and cognition comes from the VITA-
COG studies.20 This RCT included 168 adults older than 70 with mild
cognitive impairment who were either assigned to a treatment arm
(daily dose of 0.8 mg folic acid, 0.5 mg vitamin B12, and 20mg vitamin
B6) or a placebo and followed for 2 years. Smith et al20 found that
brain atrophy was 53% slower in those treated with B vitamins than
with placebo, but only in those with tHcy concentrations >13 mmol/L
at baseline.
In the present study, the rate of decline in focused attention (PoA)
and sustained attention (CoA) was slower in higher quartiles of tHcy.
This is counterintuitive, as lower concentrations of tHcy are associated
with better health outcomes, including slower rate of cognitive
decline.20 However, this is likely an effect of terminal decline, as ho-
mocysteine is a strong predictor of mortality in the very old,46,47
which may have selected more cognitively robust survivors in
higher quartiles of tHcy. The rate of decline in focused (PoA) and
sustained attention (CoA) was no longer associated with tHcy if in-
dividuals diagnosed at baseline with dementia or Alzheimer disease
were excluded.
Strengths and Limitations
In the Newcastle 85þ Study, SMMSE and attention-speciﬁc CDR
System tests were applied at 3 different time points but only over the
period of 5 and 3 years, respectively. Such follow-up periods may be
too short to detect relationships with 1-C metabolism biomarkers.43
However, due to the advanced age of the participants, it is likely
that cognitive decline was far more rapid than in younger populations,
and the SMMSE as well as the CDR Systemwould be able to detect this
decline over 5 and 3 years, respectively. Although there is no gold
standard on how to evaluate cognitive performance, the SMMSE has a
well-known ceiling effect of 30 points and a cognitive decline from
above 30 points would not be captured.48 Also for this reason, it has
been suggested that the SMMSE might not be sensitive enough to
detect subtle cognitive changes typical of most nutritional in-
terventions.49 Cognitive function is a strong predictor of mortality.
Therefore, because participants with cognitive impairment weremore
likely to be lost to follow-up due to death, this could potentially dilute
the cognitive decline results.
In the Newcastle 85þ Study, 28% of the participants were cogni-
tively impaired (SMMSE 25) at baseline. Reverse causality cannot be
fully excluded for any cross-sectional associations among homocys-
teine, folate, and cognitive performance. Finally, RBC folate, plasma
vitamin B12, and tHcy measurements were available at baseline only,
which may not reﬂect their status at other time points and lead to
underestimation of their association with cognitive function.38
Conclusion
The results suggest that tHcy and RBC folate, but not plasma
vitamin B12, concentrations are predictive of better global cognition in
the very old at baseline but not rate of cognitive decline. These results
warrant conﬁrmation by RCTs with enough follow-up time and suf-
ﬁcient power to detect cognitive decline.
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Table A1
Association Between Folate, Vitamin B12, and Homocysteine and Prevalent Cognitive Impairment at Baseline and Incident Cognitive Impairment After 5 Years (SMMSE25) in
the Newcastle 85þ Study
Prevalent Cognitive Impairment Incident Cognitive Impairment
Model 1 Model 2 Model 1 Model 2
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
RBC folate, nmol/L
Q2 (612e870) 0.77 (0.44e1.33) .35 0.73 (0.40e1.31) .29 1.68 (0.68e4.14) .26 1.68 (0.61e4.65) .31
Q3 (870e1280) 0.74 (0.43e1.28) .29 0.71 (0.38e1.30) .26 2.40 (1.02e5.65) .05 2.59 (0.96e7.02) .06
Q4 (>1280) 0.84 (0.49e1.45) .53 0.73 (0.40e1.34) .31 1.10 (0.42e2.87) .84 0.84 (0.27e2.67) .88
Plasma vitamin B12, pmol/L
Q2 (170e232) 0.80 (0.46e1.40) .44 0.64 (0.35e1.18) .16 1.15 (0.52e2.53) .73 1.41 (0.56e3.53) .46
Q3 (232e325) 1.06 (0.62e1.81) .84 1.03 (0.57e1.87) .93 0.64 (0.26e1.54) .32 0.61 (0.23e1.66) .34
Q4 (>325) 0.89 (0.51e1.54) .66 0.67 (0.36e1.23) .19 0.85 (0.36e2.03) .72 1.12 (0.40e4.11) .84
Total homocysteine, mmol/L
Q2 (13.5e16.7) 0.99 (0.56e1.75) .96 1.05 (0.57e1.96) .87 1.12 (0.50e2.54) .79 1.71 (0.68e4.30) .26
Q3 (16.7e21.4) 1.18 (0.67e2.09) .57 1.40 (0.75e2.60) .29 0.79 (0.34e1.88) .60 0.97 (0.37e2.56) .96
Q4 (>21.4) 1.55 (0.89e2.69) .13 2.15 (1.12e4.11) .02 1.10 (0.46e2.64) .83 1.81 (0.63e5.25) .27
Quartile 1 (<612 nmol/L RBC folate, <170 pmol/L plasma vitamin B12, and <13.5 tHcy, respectively) was used as the reference category (1.00) for all models. Model 1 is
unadjusted, Model 2 is adjusted for alcohol intake, smoking status, APOE genotype (rs429358 and rs7412), sex, education, BMI, depression, hypertension, diabetes type 1 and 2,
history of cardiovascular diseases, and physical activity. RBC folate and plasma vitamin B12 models were additionally adjusted for tHcy and the homocysteine model for renal
impairment.
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